Verificar estado da encomenda

Faça parte de uma comunidade de amantes de livros de todo o mundo e tenha acesso a uma série de benefícios. Crie uma conta gratuitamente

Correio DHL 7.99 € Correio DPD 4.49 € Ponto DPD 3.99 € Correio GLS 5.49 € Correio MRW 5.49 € Ponto GLS 4.49 €

Contacto

Como comprar

Ajuda

A minha conta

▸ Vazio :-(

Pharmagellan Guide to Biotech Forecasting and Valuation

Name: Pharmagellan Guide to Biotech Forecasting and Valuation
Brand: Pharmagellan, LLC
SKU: 33480497
Price: 94.82 EUR
Availability: InStock
Author: Seth Robey
ISBN: 9780998407500

Seth Robey

Andrew Matthews

Língua

Inglês

Livro Capa mole

Código Libristo: 33480497

Editoras Pharmagellan, LLC, janeiro 2017

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—th... Descrição completa

Código Libristo: 33480497

230 b

94.82 €

Armazenamento externo Envio em 14-21 dias

Até 30 dias para devoluções

Os clientes também compraram

Pharmagellan Guide to Analyzing Biotech Clinical Trials Frank S. David

Capa mole

64.96 €

Biotechnology Valuation - An Introductory Guide Karl Keegan

Livro de capa dura

74.95 €

Intelligent Asset Allocator: How to Build Your Portfolio to Maximize Returns and Minimize Risk William J. Bernstein

Capa mole

18.65 €

Market Wizards Jack D Schwager

Capa mole

22.29 €

Fundamentals of Clinical Trials Lawrence M. Friedman

Capa mole

53.16 €

Investing for Growth Terry Smith

Livro de capa dura

28.74 €

Most Important Thing Illuminated Marks

Livro de capa dura

22.99 €

Investment Philosophies Damodaran

Livro de capa dura

63.35 €

Berkshire Hathaway Letters to Shareholders Warren Buffett

Livro de capa dura

48.72 €

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.

THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.

• Vetted benchmarks for key drivers of income, expenses, and valuation.

• Proprietary analyses by Pharmagellan's experienced consulting team.

• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.

Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.